Vaccine, DTP-HIB


Concise Prescribing Info
Dosage Details
Intramuscular
Active immunisation against diphtheria, tetanus, pertussis and Haemophilus influenza
Child: ≥2 months to <6 years As primary immunisation: 3 doses of 0.5 mL via deep inj into the anterolateral muscles of the thigh or the deltoid muscles of the upper arm with 2-month intervals. Booster dose: 0.5 mL approx 6-12 months after last dose. Refer to literature as dosage may vary with brand and local guidelines.
Contraindications
Hypersensitivity. History of encephalopathy within 7 days with pertussis vaccine. Progressive neurological disorder (e.g. infantile spasms, uncontrolled epilepsy, or progressive encephalopathy).
Special Precautions
Patient with family history of seizures; personal history of Guillain-Barre syndrome within 6 weeks of tetanus vaccine, ≥40.5°C temperature, hypotonic-hyporesponsive episode or crying for ≥3 hours within 48 hours or seizures within 3 days of pertussis vaccine; immunosuppression, severe febrile illness, bleeding disorder, thrombocytopenia. Postpone vaccination in patients with acute infection or severe febrile illness.
Adverse Reactions
Significant: Fever (≥40.5°C temperature), hypotonic-hyporesponsive episode, inconsolable crying, irritability, seizures; oedematous reactions with erythema, purpura, cyanosis; syncope, Guillain-Barre syndrome, brachial neuritis.
Gastrointestinal disorders: Vomiting, diarrhoea, nausea.
General disorders and administration site conditions: Malaise, inj site reactions (e.g. tenderness, pain, oedema, erythema).
Metabolism and nutrition disorders: Appetite loss.
Nervous system disorders: Somnolence.
Psychiatric disorders: Restlessness, nervousness.
Skin and subcutaneous tissue disorders: Erythema, rash, pruritus.
Vascular disorders: Pallor.
Potentially Fatal: Hypersensitivity or anaphylaxis reactions.
MonitoringParameters
Monitor for signs of anaphylaxis and syncope for 15 minutes after injection.
Drug Interactions
Decrease effect with immunosuppressive agents (e.g. corticosteroids, antimetabolites).
Lab Interference
May interfere with urine antigen detection for Haemophilus influenzae type b infection for 2 weeks.
Action
Description: DTP-HIB vaccine, a combined vaccine of adsorbed diphtheria, tetanus toxoids, acellular pertussis and of Haemophilus influenzae type b conjugate vaccines, promotes immunity against diphtheria, tetanus, pertussis and Haemophilus influenzae type b infections.
Storage
Store between 2-8°C. Do not freeze.
ATC Classification
J07AG52 - haemophilus influenzae B, combinations with pertussis and toxoids ; Belongs to the class of hemophilus influenzae B bacterial vaccines.
Disclaimer: This information is independently developed by MIMS based on Vaccine, DTP-HIB from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in